← Eichor
Study identifier: NCT05270200 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Single Arm Study of Post-transplant Azacitidine and Chidamide for Prevention of Acute Myelogenous Leukemia Relapse

Condition: Leukemia, Myeloid, Acute  ·  Sponsor: Zhujiang Hospital

PhasePhase 1/Phase 2
Planned participants40
Who can joinAll sexes, 18 Years to 60 Years
Healthy volunteersNo

About this study

The goal of this clinical research study is to learn if azacitidine combined with Chidamide will help to control the disease in patients with high-risk AML after an allogeneic stem cell transplant. The safety of this combination will also be studied.

This description comes directly from the study's public registry record.

Talk to the study team

Rui Huang, Doctor  ·  +8615918528317  ·  Rachelchn@163.com

Yunqing Wang, Bachelor  ·  +8618585509970  ·  Wangyun7q@163.com

Always discuss trial participation with your own doctor first.

Locations (1)

Nanfang Hospital of Southern Medical UniversityGuanzhou, Guandong, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05270200